Answers are grounded in this paper and cite their sources.
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).
No takes yet. Share an insight, caveat, or question.
Madhi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: